By Chris Wack

Solid Biosciences has been granted orphan drug designation from the U.S. Food and Drug Administration for SGT-003, the company's next-generation Duchenne muscular dystrophy gene therapy candidate.

The life-science company's SGT-003 received Fast Track Designation last month.

The company said it is currently in the process of securing approvals from the institutional review boards at the clinical trial sites for the planned Phase 1/2 clinical trial of SGT-003 and expects to begin patient screening shortly thereafter.

Patient dosing in the trial is expected to begin in mid-to-late first quarter of 2024.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 16, 2024 08:35 ET (13:35 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Grafico Azioni Solid Biosciences (NASDAQ:SLDB)
Storico
Da Feb 2025 a Mar 2025 Clicca qui per i Grafici di Solid Biosciences
Grafico Azioni Solid Biosciences (NASDAQ:SLDB)
Storico
Da Mar 2024 a Mar 2025 Clicca qui per i Grafici di Solid Biosciences